Jurnal
SINTA 1
COVID-19 Infection in Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitor in Makassar, Indonesia: A Six-Case Report and Literature Review
ACTA MEDICA INDONESIANA · Vol. 55 No. 3 (2023)
ISSN 2338-2732, 0125-9326
Terbit 2023-11-01
Penerbit The Indonesian Society of Internal Medicine
Bahasa eng
Abstrak
Management of chronic myeloid leukemia (CML) in patients who are infected with COVID-19 is a challenging task due to disease-related or treatment-related factors that place such patients at a higher risk of complications. However, a low-infectivity-rate mechanism has been proposed by some researchers. In CML patients with COVID-19 infection, the most important treatment-related factor involves tyrosine kinase inhibitors (TKIs). In this case report, six patients with chronic-phase CML who experienced COVID-19 of mild–moderate severity all continued to receive TKI treatment for CML concurrently with COVID-19 treatment. All patients fully recovered. In the present study, we also review four other cases of COVID-19 infection in CML patients. Outcomes for TKI-treated CML patients who contract COVID-19 are influenced by many factors. Tyrosine kinase inhibitor therapy may benefit CML patients due to its antiviral effect, but the interaction between TKIs and drugs used for COVID-19 treatment requires careful monitoring. An individual approach is needed in every case.
Jaringan kolaborasi para penulis
11 penulis ·
26 tautan kepenulisan bersama
Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.
Hasanuddin University Afiliasi tidak diketahui
Organisasi berbeda
Organisasi sama
Afiliasi tidak diketahui
Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.
Sumber metadata: OAI-PMH (metadata jurnal) http://www.actamedindones.org/index.php/ijim/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 8 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
<dc:title xml:lang="en-US">COVID-19 Infection in Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitor in Makassar, Indonesia: A Six-Case Report and Literature Review</dc:title>
<dc:creator>Harjianti, Tutik</dc:creator>
<dc:creator>Benyamin, Fachruddin</dc:creator>
<dc:creator>Minhajat, Rahmawati</dc:creator>
<dc:creator>Saleh, Sahyuddin</dc:creator>
<dc:creator>Bayu, Dimas</dc:creator>
<dc:creator>Pababbari, Wahyudi</dc:creator>
<dc:subject xml:lang="en-US">Chronic Myeloid Leukemia</dc:subject>
<dc:subject xml:lang="en-US">Tyrosine Kinase Inhibitor</dc:subject>
<dc:subject xml:lang="en-US">COVID-19</dc:subject>
<dc:subject xml:lang="en-US">Case Report</dc:subject>
<dc:subject xml:lang="en-US">hematology and oncology medic</dc:subject>
<dc:description xml:lang="en-US">Management of chronic myeloid leukemia (CML) in patients who are infected with COVID-19 is a challenging task due to disease-related or treatment-related factors that place such patients at a higher risk of complications. However, a low-infectivity-rate mechanism has been proposed by some researchers. In CML patients with COVID-19 infection, the most important treatment-related factor involves tyrosine kinase inhibitors (TKIs). In this case report, six patients with chronic-phase CML who experienced COVID-19 of mild–moderate severity all continued to receive TKI treatment for CML concurrently with COVID-19 treatment. All patients fully recovered. In the present study, we also review four other cases of COVID-19 infection in CML patients. Outcomes for TKI-treated CML patients who contract COVID-19 are influenced by many factors. Tyrosine kinase inhibitor therapy may benefit CML patients due to its antiviral effect, but the interaction between TKIs and drugs used for COVID-19 treatment requires careful monitoring. An individual approach is needed in every case.</dc:description>
<dc:publisher xml:lang="en-US">The Indonesian Society of Internal Medicine</dc:publisher>
<dc:date>2023-11-01</dc:date>
<dc:type>info:eu-repo/semantics/article</dc:type>
<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
<dc:type xml:lang="en-US">case report</dc:type>
<dc:format>application/pdf</dc:format>
<dc:identifier>http://www.actamedindones.org/index.php/ijim/article/view/2346</dc:identifier>
<dc:source xml:lang="en-US">Acta Medica Indonesiana; Vol. 55 No. 3 (2023): Acta Medica Indonesiana; 332</dc:source>
<dc:source>2338-2732</dc:source>
<dc:source>0125-9326</dc:source>
<dc:language>eng</dc:language>
<dc:relation>http://www.actamedindones.org/index.php/ijim/article/view/2346/pdf</dc:relation>
<dc:rights xml:lang="en-US">Copyright (c) 2023 Tutik Harjianti, Fachruddin Benyamin, Rahmawati Minhajat, Sahyuddin Saleh, Dimas Bayu, Wahyudi Pababbari</dc:rights>
</oai_dc:dc>
Sitasi dan pengindeksan
OpenAlex
Belum diperiksa
Crossref
Tidak ditemukan
Jumlah menurut tiap indeks pada 9 Nov 2026; setiap indeks menghitung sitasi dengan cara berbeda.
Sitasi artikel ini
APA 7
Harjianti, T., Benyamin, F., Minhajat, R., Saleh, S., Bayu, D., & Pababbari, W. (2023). COVID-19 Infection in Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitor in Makassar, Indonesia: A Six-Case Report and Literature Review. ACTA MEDICA INDONESIANA, 55(3). http://www.actamedindones.org/index.php/ijim/article/view/2346
Salin
IEEE
T. Harjianti, F. Benyamin, R. Minhajat, S. Saleh, D. Bayu, and W. Pababbari, “COVID-19 Infection in Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitor in Makassar, Indonesia: A Six-Case Report and Literature Review,” ACTA MEDICA INDONESIANA, vol. 55, no. 3, 2023.
Salin
Dibuat dari metadata jurnal; periksa nama penulis sebelum dipakai.